Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

YN001-004 hos pasienter med koronar aterosklerose i Australia

21. september 2026 oppdatert av: Beijing Inno Medicine Co., Ltd.

En fase Ⅱa klinisk studie for å evaluere effektiviteten og sikkerheten til YN001 hos pasienter med koronar aterosklerose i Australia

This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a multicenter, randomized, open label, parallel-group, proof of concept study. It is designed to determine if the study drug, called YN001, administered in addition to evolocumab can effectively reduce the total amount of plaque formed in the coronary artery as measured by CCTA from baseline to week 13.

A total of 24 patients with coronary atherosclerosis are expected to be enrolled and will be randomly assigned in a 1:1 ratio to 1 of 2 YN001 treatment arms (12 patients per arm) with 2 different dose levels for 12 weeks.

The study will be comprised of a maximum 41-day screening period (Day -42-Day -2), a baseline period (Day-1), a treatment and observation period (W1D1- W13D7), and a safety follow-up period (14 days post last dose).

Studietype

Intervensjonell

Registrering (Faktiske)

3

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Tugun, Australia
        • John Flynn Private Hospital
    • Australian Capital Territory
      • Canberra, Australian Capital Territory, Australia
        • Canberra Hospital
    • New South Wales
      • Albury, New South Wales, Australia, 1125
        • Albury Wodonga Private Hospital
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • Sunshine Coast University Private Hospital
    • Victoria
      • Melbourne, Victoria, Australia, 3025
        • Altona Clinical Research
      • Melbourne, Victoria, Australia, 3199
        • Peninsula Heart Centre

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Fully understand the purposes, features, and methods of the study, and sign the ICF before performing any assessment.
  2. Male or female Australia patients between 18 and 75 years.
  3. Patients diagnosed with coronary atherosclerosis, and at least 1 vessel with diameter stenosis determined by coronary computed tomography angiography (CTA).
  4. Female patients must be non-pregnant and non-lactating, and females of childbearing potential (including a female partner of a male patient) must agree to use 1 effective contraception method from the screening period to 3 months after receiving their last dose of the study drug. In addition, male patients must be willing to refrain from sperm donation during this time.
  5. Willing and able to comply with the requirements of protocol to the best of the patient's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization.
  4. Contraindication for coronary CTA (e.g., known history of anaphylactic contrast reactions).
  5. Multi-vessel severe disease.
  6. Recent acute ST-segment elevation myocardial infarction (STEMI) occurred within 2 weeks prior to randomization.
  7. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia.
  8. Prior treatment with CABG, heart transplantation, SAVR/TAVR, etc., or CABG, heart transplantation, SAVR/TAVR, etc., is required or planned during the study.
  9. PCI performed within 4 weeks prior to randomization or PCI is required or planned during study treatment.
  10. New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction (LVEF) <40%.
  11. Recent clinically evident stroke occurred within 6 months prior to randomization (except for TIA).
  12. Presenting with history of myopathy/myalgia, or susceptible to myopathy/rhabdomyolysis.
  13. Known inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding within 6 months prior to randomization.
  14. Evidence of major diseases that not recovered within 2 weeks prior to randomization, or major surgery is expected during the study.
  15. Presenting with history of malignancy (except in patients who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  16. Presence of any type of autoimmune disease.
  17. Allergy to multiple food or drugs or known sensitivity to any components to be administered during dosing
  18. Life expectancy is less than 1 year.
  19. Systolic blood pressure of ≥150 mmHg at final screening despite antihypertensive therapy.
  20. Known familial hypercholesterolemia
  21. Triglycerides≥400 mg/dl (4.5 mmol/l) at final screening.
  22. Active liver disease or hepatic dysfunction defined by any of ALT, AST, or total bilirubin > 2 times upper limit of normal (ULN) at final screening.
  23. Presence of renal insufficiency.
  24. Untreated or inadequately treated hypothyroidism defined by thyroid stimulating hormone (TSH) > 1.5 times ULN at final screening.
  25. Poorly controlled (defined by HbA1c > 9%) type 2 diabetes mellitus.
  26. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  27. Current smoker who has smoked an average of≥5 cigarettes (or equivalent) per day over the preceding year.
  28. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the patient to participate in this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dose 1 treatment arm

Dose 1 YN001 will be administrated intravenously weekly.

Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Evolocumab 140 mg will be administered subcutaneously every 2 weeks.

Andre navn:
  • Repatha®
Eksperimentell: Dose 2 treatment arm

Dose 2 YN001 will be administrated intravenously weekly.

Evolocumab 140 mg will be administered subcutaneously every 2 weeks.

Andre navn:
  • Repatha®

Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in coronary plaque characteristics (volume and composition)
Tidsramme: From baseline to Week 13

Evaluating YN001 on top of evolocumab therapy in changing coronary plaque volume assessed by coronary computed tomography angiography (CCTA).

From baseline to Week 13

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in mean of mean carotid IMT
Tidsramme: From baseline to Week 13

Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

From baseline to Week 13
Change in mean of mean carotid IMT
Tidsramme: From baseline to Week 5

Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

From baseline to Week 5
Change in mean of mean carotid IMT
Tidsramme: From baseline to Week 9

Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

From baseline to Week 9
Change in mean peri-coronary Fat attenuation index (FAI)
Tidsramme: From baseline to Week 13

Evaluating YN001 on top of evolocumab therapy in changing inflammation using the peri-coronary FAI value measured by quantitative CTA analysis.

From baseline to Week 13
The safety profile of YN001
Tidsramme: From baseline to Week 15

Incidence of Adverse events (AEs)/Serious adverse events (SAEs)

From baseline to Week 15
Plasma concentration of total and free drug
Tidsramme: From Week 1 to Week 13

Plasma concentration of total and free drug at pre-dose (0 h) and at the end of infusion

From Week 1 to Week 13
Population pharmacokinetics (PK)
Tidsramme: From Week 1 to Week 13

Plasma PK parameter (AUC) and patient covariates of interest will be evaluated graphically and in the population PK model.

From Week 1 to Week 13

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Immunogenicity(ADA) analysis
Tidsramme: From Week 1 to Week 13

The proportion of patients who develop anti-drug antibodies (ADA) following drug administration.

From Week 1 to Week 13
Immunogenicity (APA)analysis
Tidsramme: From screening to Week 13

The proportion of patients with pre-exsiting anti-PEG antibodies (APA), treatment emergent APA or treatment boosted APA following drug administration.

From screening to Week 13
Exploratory dose-response analysis of plaque volume
Tidsramme: From Week 1 to Week 13

Exploratory dose-response analysis will be performed by comparing the difference of coronary plaque volume changing between 2 different dose levels

From Week 1 to Week 13
Exploratory dose-response analysis of AEs
Tidsramme: From Week 1 to Week 13

Exploratory dose-response analysis will be performed by comparing the difference of incidence of AEs between 2 different dose levels

From Week 1 to Week 13

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Teresa Chen, PhD, Beijing Inno Medicine Co., Ltd.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. februar 2026

Primær fullføring (Faktiske)

22. juli 2026

Studiet fullført (Faktiske)

22. juli 2026

Datoer for studieregistrering

Først innsendt

14. november 2024

Først innsendt som oppfylte QC-kriteriene

19. november 2024

Først lagt ut (Faktiske)

22. november 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • YN001-004

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .